Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc
Your view on BDRX
Overview
What the company does, where it operates, and who runs it.
About Biodexa Pharmaceuticals Plc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Stephen Anthony Stamp
- Headquarters
- 1 Caspian Point, Cardiff, GB
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Stephen Anthony Stamp
- Headquarters
- 1 Caspian Point, Cardiff, GB
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain.
Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma.
In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.
It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Biodexa Pharmaceuticals Plc, and the rating behind it. BDRX last traded at $0.66; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Biodexa Pharmaceuticals Plc. Starting points for Biodexa Pharmaceuticals Plc: EPS -$70.50, beta 1.19 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Biodexa Pharmaceuticals Plc. Biodexa Pharmaceuticals Plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Biodexa Pharmaceuticals Plc. Trailing twelve-month EPS for Biodexa Pharmaceuticals Plc stands at -$70.50. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Biodexa Pharmaceuticals Plc. Biodexa Pharmaceuticals Plc has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Biodexa Pharmaceuticals Plc valued side by side against its closest peers. Biodexa Pharmaceuticals Plc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Biodexa Pharmaceuticals Plc, and how their positions are changing. At a $492,509 market value, institutional positions materially move Biodexa Pharmaceuticals Plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Biodexa Pharmaceuticals Plc executives and directors. Shares of Biodexa Pharmaceuticals Plc have traded between $4.27 and $92.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Biodexa Pharmaceuticals Plc. Biodexa Pharmaceuticals Plc is a $492,509 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Biodexa Pharmaceuticals Plc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Biodexa Pharmaceuticals Plc. Coverage tracks Biodexa Pharmaceuticals Plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.